Optos Overview
- Year Founded
-
1992
- Status
-
Acquired/Merged
- Employees
-
650
- Latest Deal Type
-
Grant
- Financing Rounds
-
5
- Investments
-
3
Optos General Information
Description
Manufacturer of retinal imaging devices intended to serve eyecare professionals. The company offers ultra-widefield retinal imaging, fundus imaging, retina medical devices, optomap, clinically validated, OCT and retinal imaging products, thereby enabling eyecare professionals to discover, diagnose, document and treat ocular pathology that may go undetected using traditional examination techniques and equipment.
Contact Information
Website
www.optos.com(Operating Subsidiary)
Corporate Office
- Queensferry House
- Carnegie Campus, Enterprise Way
- Dunfermline KY11 8GR
- Scotland, United Kingdom
Corporate Office
- Queensferry House
- Carnegie Campus, Enterprise Way
- Dunfermline KY11 8GR
- Scotland, United Kingdom
Optos Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Optos Comparisons
Industry
Financing
Details
Optos Competitors (3)
One of Optos’s 3 competitors is Lumenis, a Private Equity-Backed company based in Yokneam, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lumenis | Private Equity-Backed | Yokneam, Israel | ||||
| Boston Scientific | Corporation | Marlborough, MA | ||||
| ZEISS (Germany) | Formerly PE-Backed | Oberkochen, Germany |
Optos Patents
Optos Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202509405-D0 | Opthalmic system and associated methods | Pending | 13-Jun-2025 | ||
| EP-4834199-A1 | Head support for an ophthalmic imaging instrument | Pending | 28-Apr-2025 | ||
| GB-202506339-D0 | Head support for an ophthalmic imaging instrument | Pending | 28-Apr-2025 | ||
| US-20260334775-A1 | Head support for an ophthalmic imaging instrument | Pending | 28-Apr-2025 | ||
| JP-2026179214-A | Head support for ophthalmic imaging equipment | Pending | 28-Apr-2025 |
Optos Signals
Optos Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Optos Investments & Acquisitions (3)
Optos’s most recent deal was a Corporate Asset Purchase with Escalon Medical (Software Related Assets Associated with AXIS Platform) for . The deal was made on 23-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Escalon Medical (Software Related Assets Associated with AXIS Platform) | 23-Jan-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Opko (Instrumentation Division) | 11-Oct-2011 | Merger/Acquisition | Diagnostic Equipment | ||
| Opto Global | 13-Dec-2010 | Merger/Acquisition | Other Devices and Supplies |
Optos FAQs
-
When was Optos founded?
Optos was founded in 1992.
-
Where is Optos headquartered?
Optos is headquartered in Dunfermline, United Kingdom.
-
What is the size of Optos?
Optos has 650 total employees.
-
What industry is Optos in?
Optos’s primary industry is Diagnostic Equipment.
-
Is Optos a private or public company?
Optos is a Private company.
-
What is Optos’s current revenue?
The current revenue for Optos is .
-
How much funding has Optos raised over time?
Optos has raised $54.1M.
-
Who are Optos’s investors?
Amadeus Capital Partners, Archangel Investors, and Truetide have invested in Optos.
-
Who are Optos’s competitors?
Lumenis, Boston Scientific, and ZEISS (Germany) are competitors of Optos.
-
When was Optos acquired?
Optos was acquired on 11-Sep-2020.
-
Who acquired Optos?
Optos was acquired by Nikon (Tokyo).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process